Cat. No. | Product name | CAS No. |
DC8651 |
CO-1686 hydrobromide
Featured
CO-1686 hydrobromide is a novel, irreversible and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M (IC50=21 nM). |
1446700-26-0 |
DC7106 |
Rociletinib (CO-1686)
Featured
CO-1686 is a novel, irreversible and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M(IC50=21 nM). |
1374640-70-6 |
DC8892 |
CP724714
CP-724714 is a potent, selective inhibitor of HER2/ErbB2 with IC50 of 10 nM, >640-fold selectivity against EGFR, InsR, IRG-1R, PDGFR, VEGFR2, Abl, Src, c-Met etc in cell-free assays. Phase 2. |
537705-08-1 |
DC9665 |
EAI045
Featured
EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor. |
1942114-09-1 |
DC9534 |
EBE-A22
Featured
EBE-A22 is a derivative of PD 153035 which can inhibit ErbB-1-phosphorylation, whereas EBE-A22 is inactive. |
229476-53-3 |
DC11018 |
EGFR-IN-99
Featured
EGFR-IN-99 (compound 1a) is a potent EGFR and HER2 Exon 20 insertion mutant inhibitor. EGFR-IN-99 has excellent antiproliferative activity against DFCI127 cells, with an EC50 of 11.5 nM. EGFR-IN-99 can be used for the research of non-small cell lung cancer (NSCLC). |
2068806-31-3 |
DC2101 |
Erlotinib free base
Featured
Erlotinib (OSI-744; NSC 718781; R1415) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. |
183321-74-6 |
DC3139 |
Erlotinib hydrochloride
Featured
Erlotinib HCl is an HER1/EGFR inhibitor with IC50 of 2 nM. |
183319-69-9 |
DC2103 |
Gefitinib (ZD1839)
Featured
Gefitinib (Iressa, ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. |
184475-35-2 |
DC10596 |
Lavendustin C (HDBA)
Featured
HDBA, a derivative of a Streptomyces griseolavendus butyl acetate extract, is a potent inhibitor of epidermal growth factor (EGF) receptor-associated tyrosine kinase with an IC50 value of 0.012 µM. |
125697-93-0 |
DC11366 |
HKI 357
HKI 357 is an irreversible dual inhibitor of the EGF receptor tyrosine kinases EGFR and HER2 (IC50s = 34 and 33 nM, respectively). |
848133-17-5 |
DC8819 |
Olmutinib (HM61713; BI-1482694)
Featured
HM-61713 (BI-1482694) is an orally available small molecule, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. |
1353550-13-6 |
DC12259 |
HS-10296 hydrochloride
HS-10296 hydrochloride is an orally available and third-Generation inhibitor of epidermal growth factor receptor (EGFR)-activating mutations and T790M-resistant mutation with limited activity against wild-type EGFR. |
2134096-03-8 |
DC12494 |
HS-10296
Featured
HS-10296 is an orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. |
1899921-05-1 |
DC8817 |
Icotinib Hydrochloride
Featured
Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an IC(50) of 5 nM, including it's mutants of EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R). |
1204313-51-8 |
DC7427 |
Icotinib
Icotinib(BPI-2009) is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an IC(50) of 5 nM, including it's mutants of EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R). |
610798-31-7 |
DCAPI1512 |
Lapatinib
Featured
Lapatinib |
231277-92-2 |
DC3143 |
Lapatinib ditosylate
Featured
Lapatinib Ditosylate (GW572016, GW2016, Tykerb, Tyverb) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively. |
388082-78-8 |
DC9433 |
Lapatinib (ditosylate)
Lapatinib ditosylate(GW-572016 ditosylate) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively. |
388082-77-7 |
DC10598 |
lavendustin A
Featured
Lavendustin A is a selective inhibitor of epidermal growth factor (EGF) receptor-associated tyrosine kinase (IC50 = 11 nM) that was first isolated from a Streptomyces culture filtrate. |
125697-92-9 |
DC11900 |
Lazertinib
Featured
Lazertinib (YH25448, GNS-1480) is a highly potent, mutant-selective, irreversible, brain-penetrant and orally active EGFR tyrosine-kinase inhibitors for both the T790M mutation and activating EGFR mutations |
1903008-80-9 |
DC10915 |
mutant EGFR inhibitor B30
Featured
mutant EGFR inhibitor B30 is a potent, selective, next-generation EGFR mutants inhibitor with IC50 of 1.1 and 7.2 nM for EGFRL858R and EGFRL858R/T790M/C797S, respectively. |
2225887-26-1 |